Diabetes UK: Alcohol study not a “green light”

54dbc64f-34e4-413f-b3d0-44f898cb928darticleimage.jpg

31 Jul 2017 --- A recent study in which researchers from Denmark suggest that drinking moderately three or four times a week may reduce the risk of diabetes shouldn’t be taken as a “green light” to drink to excess due to the “complex” nature of the disease, according to a Diabetes UK response.

The study, published in Diabetologia, the journal of the European Association for the Study of Diabetes, outlines that people who drink three to four times per week are less likely to develop Type 2 diabetes than those who never drink.

In response to the study, Dr. Emily Burns, Head of Research Communications at Diabetes UK, says: “Type 2 diabetes risk is complex. Several factors contribute to it, including family history, ethnic background, age and being overweight. While these findings are interesting, we wouldn’t recommend people see them as a green light to drink more than the existing NHS guidelines. Especially as the impact of regular alcohol consumption on the risk of Type 2 will be different from one person to the next.”

“Type 2 diabetes is a serious condition, and around three in five cases can be prevented or delayed by eating healthily, moving more and losing weight if you’re overweight. If you’re worried about your risk of developing the condition, we’d advise you to speak to a healthcare professional,” Burns adds.

Diabetes UK also calls the finding “very interesting” in its response but emphasizes that further research is needed as people may change their drinking habits over time, while researchers in the study recorded drinking habits only once. To better understand how alcohol might affect the risk of Type 2 diabetes, it says, future research would need to follow people for a longer period and record any changes in their alcohol intake.

by Paul Creasy

Related Articles

Nutrition & Health News

“Beetroot pill” could help save reduce the risk of kidney failure after heart x-ray

22 Feb 2018 --- The humble beetroot may be the key to reducing the risk of kidney failure in patients having a heart x-ray. This is according to research led by Queen Mary University of London, which has embarked on a new research project funded by national charity Heart Research UK will look into whether dietary inorganic nitrate found commonly in beetroot could be used in pill form to prevent one of the most common causes of kidney failure in hospital.

Business News

Dynamic OTC marketplace: Albertsons and Rite Aid merge, Amazon enters the fray

21 Feb 2018 --- Albertsons Companies, one of the US’ largest grocery retailers, and leading drugstore chain Rite Aid Corporation have announced a definitive merger agreement, creating a retail behemoth with US$83 billion in annual revenue. The move is thought to give the integrated company more weight to compete with bigger chains in an industry anxious about the reported entry of Amazon.com.

Nutrition & Health News

Chronic heavy drinking major risk factor for dementia: The Lancet

21 Feb 2018 --- Excessive alcohol use is a major risk factor for onset of all types of dementia, especially early-onset dementia, according to a French nationwide observational study, published in The Lancet Public Health journal. Previous research has shown mixed results regarding the effect of alcohol on cognitive health, with some studies showing a possible benefit of light to moderate drinking, while others have found detrimental effects of heavy drinking on dementia risk.

Nutrition & Health News

Low-fat and low-carb diets equally effective, Stanford study finds

21 Feb 2018 --- After years of debate, a new study at the Stanford University School of Medicine has found that neither a low-fat nor a low-carb diet is superior: Cutting either carbs or fats leads to a reduction of excess weight in about the same proportion, according to the study. The study also looked into whether insulin levels or a specific genotype pattern could predict an individual's success on either diet. The answer, in both cases, was no.

Business News

Lonza to expand Florida encapsulation capabilities amid product development acceleration

21 Feb 2018 --- Swiss multinational, chemicals and biotechnology company, the Lonza Group is planning to expand its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in North America. The company will install a new Harro Hӧfliger Modu-C MS encapsulation unit (Harro unit) at its integrated product development and manufacturing facility in Tampa, Florida, to strengthen production and bring its products to market faster. 

More Articles
URL : http://www.nutritioninsight.com:80/news/diabetes-uk-alcohol-study-not-a-green-light.html